The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The US Food and Drug Administration has accepted a new drug application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma.
Dr. Banerjee reviewed the BCMA-sparing clinical efficacy data from the trial and discussed the results, which showed that MeziKd significantly extended progression-free survival while offering a crucial option before or after T-cell engager therapies.
In this interview from the 2026 European Hematology Association Congress, Naseema Gangat, MBBS, a professor of medicine at the Mayo Clinic in Rochester, Minnesota, discusses
The European Commission has granted marketing authorization to epcoritamab (TEPKINLY® ) in combination with rituximab and lenalidomide (R2) for the treatment of relapsed or refractory follicular lymphoma in the second-line setting.
Warm autoimmune hemolytic anemia is a rare disease with no current approved therapy. In the trial, the investigators reported that nipocalimab had durable responses with a favorable safety profile.
To ensure long-term clinical efficacy and treatment compliance, avoiding severe off-target side effects is vital to maintaining patient well-being, Prof. Weisel stressed. “We got rid of off-target effects which are hampering life quality like fatigue, like GI toxicity,” she said. “So I think it’s a regimen reflecting the needs of the patients.”
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
![Insider_YT_Feature_Pannunzio_CLFR2_400x400[15]](https://sohoinsider.com/wp-content/uploads/2026/06/Insider_YT_Feature_Pannunzio_CLFR2_400x40015.png)
